Dana Brabbing-Goldstein1,2,3, Shay Ben-Shachar4,5. 1. Genetic Institute, Tel Aviv Medical Center, Tel Aviv, Israel. 2. Department of Obstetrics and Gynecology, The Lis Maternity Hospital, Tel Aviv University, Tel Aviv, Israel. 3. Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel. 4. Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel. shayb@clalit.org.il. 5. Clalit Research Institute, & Schneider Children's Medical Center, Ramat-Gan, Israel. shayb@clalit.org.il.
Abstract
OBJECTIVES: Phacomatoses are a group of neuro-oculo-cutaneous syndromes/ neurocutaneous disorders, involving structures arising from the embryonic ectoderm. Most of phacomatoses including the most common ones:, neurofibromatosis type I and type II (NF1, NF2) and tuberosclerosis complex (TSC), are autosomal dominant genetic disorders with full penetrance and variable expression. As no effective treatment exists, the only way to prevent the disease, is by prenatal genetic diagnosis (either chorionic villus sampling-CVS or amniocentesis-AC) and termination of pregnancy or performing preimplantation genetic testing (PGT). As the risk for an affected offspring is 50% in every pregnancy of an affected parent, prenatal, and preimplantation testing are of great importance. However, those procedures are associated with technical and ethical concerns. This chapter shortly reviews the common phacomatoses emphasizes their genetics and inheritance. We will review the common methods for prenatal and preimplantation diagnoses and discuss its use in common phacomatoses. CONCLUSION: Phacomatoses are common autosomal dominant genetic conditions with variable expression. Ante-natal genetic diagnosis is an appropriate approach for family planning in individuals affected by phacomatosis or parents of an affected child.
OBJECTIVES: Phacomatoses are a group of neuro-oculo-cutaneous syndromes/ neurocutaneous disorders, involving structures arising from the embryonic ectoderm. Most of phacomatoses including the most common ones:, neurofibromatosis type I and type II (NF1, NF2) and tuberosclerosis complex (TSC), are autosomal dominant genetic disorders with full penetrance and variable expression. As no effective treatment exists, the only way to prevent the disease, is by prenatal genetic diagnosis (either chorionic villus sampling-CVS or amniocentesis-AC) and termination of pregnancy or performing preimplantation genetic testing (PGT). As the risk for an affected offspring is 50% in every pregnancy of an affected parent, prenatal, and preimplantation testing are of great importance. However, those procedures are associated with technical and ethical concerns. This chapter shortly reviews the common phacomatoses emphasizes their genetics and inheritance. We will review the common methods for prenatal and preimplantation diagnoses and discuss its use in common phacomatoses. CONCLUSION: Phacomatoses are common autosomal dominant genetic conditions with variable expression. Ante-natal genetic diagnosis is an appropriate approach for family planning in individuals affected by phacomatosis or parents of an affected child.
Authors: Matthew D Shirley; Hao Tang; Carol J Gallione; Joseph D Baugher; Laurence P Frelin; Bernard Cohen; Paula E North; Douglas A Marchuk; Anne M Comi; Jonathan Pevsner Journal: N Engl J Med Date: 2013-05-08 Impact factor: 91.245
Authors: K Wimmer; S Yao; K Claes; H Kehrer-Sawatzki; S Tinschert; T De Raedt; E Legius; T Callens; H Beiglböck; O Maertens; L Messiaen Journal: Genes Chromosomes Cancer Date: 2006-03 Impact factor: 5.006
Authors: L M Messiaen; T Callens; G Mortier; D Beysen; I Vandenbroucke; N Van Roy; F Speleman; A D Paepe Journal: Hum Mutat Date: 2000 Impact factor: 4.878
Authors: Irene Bottillo; Terje Ahlquist; Helge Brekke; Stine A Danielsen; Eva van den Berg; Fredrik Mertens; Ragnhild A Lothe; Bruno Dallapiccola Journal: J Pathol Date: 2009-04 Impact factor: 7.996
Authors: Meena Upadhyaya; Gill Spurlock; Bisma Monem; Nick Thomas; Reinhard E Friedrich; Lan Kluwe; Victor Mautner Journal: Hum Mutat Date: 2008-08 Impact factor: 4.878
Authors: Virginia C Williams; John Lucas; Michael A Babcock; David H Gutmann; Bruce Korf; Bernard L Maria Journal: Pediatrics Date: 2009-01 Impact factor: 7.124
Authors: Roope A Kallionpää; Elina Uusitalo; Jussi Leppävirta; Minna Pöyhönen; Sirkku Peltonen; Juha Peltonen Journal: Genet Med Date: 2017-12-07 Impact factor: 8.822